相关临床试验
1
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1930
进行中（未招募）
1
100.0%
暂无批准数据
- EverGlade announced that Kate Teffer, PhD, a former ARPA-H scientific advisor, has joined the firm as a Senior Technical Strategist. - Dr. Teffer brings over 10 years of experience advising federal biomedical research organizations including ARPA-H, NIH, DoD, and VA. - She co-authored ARPA-H's Health Science Futures Mission Office's original Broad Agency Announcement and supported nearly every program launched from its founding through mid-2026. - EverGlade has secured more than $3 billion in funding and actively manages 50 programs across the federal funding lifecycle.
- VA Community Care referrals for vascular surgery nearly tripled from 21,407 in FY2020 to 62,487 in FY2025, a 192% increase driven largely by peripheral artery disease interventions. - Infrainguinal endovascular procedure payments more than quadrupled from $8.8 million to $40.2 million, with femoral-popliteal atherectomy as the highest-paid procedure code across nearly all years analyzed. - Distance from a VA facility accounted for 88% of community care referrals, and no open bypass or groin-level reconstruction procedures appeared among the top 30 paid codes. - Researchers emphasize the need for comparative effectiveness research to guide evidence-based treatment decisions as endovascular spending dominates VA Community Care vascular surgery costs.
- Belfast-based Neurovalens has secured FDA de novo approval for Modius Spero, a non-invasive medical device designed to treat post-traumatic stress disorder symptoms through electrical vestibular system stimulation. - The device delivers small electrical pulses to the skin behind each ear for 30 minutes daily, targeting deep brain areas associated with stress response and mental health regulation. - Clinical trials demonstrated that two-thirds of PTSD participants using Modius Spero reported significant and clinically meaningful symptom improvement, supporting its effectiveness as a treatment option. - The device will become available on prescription to US military veterans through the Department of Veterans Affairs starting in July, marking a significant milestone for the Northern Irish company.
- Governor Gavin Newsom signed Assembly Bill 1103 to fast-track psychedelic drug studies in California, eliminating regulatory delays that previously hindered research approval processes. - The legislation targets the urgent mental health crisis among veterans, where daily suicide rates exceed average combat deaths from Vietnam, Iraq, and Afghanistan combined. - A Stanford observational study of ibogaine treatment in 30 special forces veterans demonstrated remarkable symptom reductions of 88% for PTSD, 87% for depression, and 81% for anxiety. - The bill allows FDA-approved studies to bypass full advisory panel meetings, enabling approval within days through smaller review groups starting January 2026.
- A five-year, $18 million Department of Defense clinical trial will investigate metformin's potential to treat idiopathic pulmonary fibrosis, a life-threatening condition with median survival of just three to five years. - The groundbreaking study represents an unprecedented partnership between the VA, DOD, and Pulmonary Fibrosis Foundation, integrating 45-55 care centers with 10 VA medical centers nationwide. - Veterans face higher IPF risk than civilians and have been historically underrepresented in clinical trials, making this collaboration critical for expanding treatment access. - The trial will screen 800 patients and randomize 400 high-risk individuals to receive either metformin or placebo, with enrollment expected to begin in early 2026.
- MMJ BioPharma Cultivation has been trapped in a seven-year regulatory paradox, unable to produce pharmaceutical-grade cannabis for FDA-approved clinical trials despite passing inspections and receiving Orphan Drug Designations. - The DEA requires companies to present "bona fide supply agreements" before issuing bulk manufacturing registrations, but federal law prohibits signing such agreements without the license first. - The U.S. Department of Veterans Affairs has applied for DEA approval to import marijuana extracts from abroad for PTSD and chronic pain research, highlighting the agency's contradictory approach to domestic versus foreign cannabis supply. - The regulatory obstruction has forced legitimate pharmaceutical research overseas while blocking American companies from producing cannabis for neurological conditions like Huntington's disease and multiple sclerosis.
- Two major studies demonstrate that COVID-19 vaccines provide meaningful protection against severe outcomes, with effectiveness ranging from 24-64% depending on the endpoint measured. - Vaccine effectiveness significantly decreases over time, dropping from approximately 50% in the first two months to negative or minimal protection after six months post-vaccination. - The 2024-2025 COVID vaccine showed 29% effectiveness against emergency department visits, 39% against hospitalizations, and 64% against deaths among U.S. veterans over six months of follow-up. - Despite waning immunity, vaccines continue to provide benefits across all age groups and immunocompromised populations, supporting recommendations for annual vaccination updates.
- The University of Kansas Cancer Center and Kansas City Veteran Medical Center have established a partnership to provide veterans with access to early-phase cancer clinical trials, addressing a critical gap in cancer care. - Veterans face approximately 50,000 new cancer cases annually and higher cancer risks due to service-related exposures, yet have historically had limited access to innovative early-phase trials that test new therapies. - The collaboration provides financial and logistical support, with KU Cancer Center serving as a subsite for trials, aiming to create a replicable template for VA centers and academic cancer centers nationwide.
- A recent GAO report reveals that the Departments of Defense (DOD) and Veterans Affairs (VA) dedicated approximately $20 billion and $10 billion, respectively, to biomedical R&D from 2019 to 2023. - The study found inconsistencies in disclosing DOD support in biomedical patents, with 559 out of 3,078 patents lacking correct DOD award numbers. - The GAO report indicates that the majority of DOD- and VA-funded clinical trials registered between 2014 and 2023 had late or missing results, hindering transparency and access to crucial scientific information.
